|
||
| |||||||
|
|
Oxford, UK: 3 February 2006 – Oxford BioMedica (LSE: OXB), the leading gene therapy company, today announces that, with immediate effect, Dr Mike McDonald has been promoted to the Board as an executive director. He will maintain his title of Chief Medical Officer. His primary responsibilities include the Company’s clinical development activities and regulatory affairs. Mike has over 20 years of experience in clinical drug development and regulatory leadership. He joined Oxford BioMedica in September 2005 from Seattle Genetics, a US-based biotechnology company, where he was Chief Medical Officer. Mike spent nine years with Eli Lilly serving as Worldwide Vice President, Clinical Research and Medical Affairs, and was previously at SmithKline Beecham for seven years where he was involved in worldwide clinical development, regulatory management and was a member of the pharmaceutical development strategy committee. From these positions Dr McDonald contributed to the successful registration and commercialisation of many important pharmaceuticals. He received his medical degree from Edinburgh University, he is a member of the Royal College of Physicians in London, holds a Diploma in Pharmaceutical Medicine and is a Fellow of the Faculty of Pharmaceutical Physicians. Commenting on the Board appointment, Professor Alan Kingsman, Chief Executive of Oxford BioMedica, said: “Mike has already made a significant and valuable contribution to the Company since joining last year and has been instrumental in the preparations for our planned Phase III trial of TroVax in renal cell carcinoma. We are delighted to welcome him to the Board.” There is no other information to be disclosed under Paragraph 9.6.13 R of the Listing Rules. ENDS
Notes to editors:Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. In oncology, the pipeline includes an immunotherapy and a gene therapy in multiple Phase II trials, and a preclinical targeted antibody therapy in collaboration with Wyeth. In neurotherapy, the Company’s lead product is a gene therapy for Parkinson’s disease, which is expected to enter clinical trials in 2006, and four further preclinical candidates. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 70 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Sigma-Aldrich, Viragen, MolMed and Kiadis; and has licensed technology to a number of companies including Merck & Co, Biogen Idec and Pfizer. Further information is available at www.oxfordbiomedica.co.uk |
|
| ||||||||
